New drug treatments for ocular allergies

Expert Review of Ophthalmology

Volumn 2, Issue 3, 2007, Pages 397-408

  Leonardi, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

allergic conjunctivitis; antihistamines; cyclosporine A; epinastine; ketotifen; mast cell stabilizers; olopatadine; tear cytokines; vernal keratoconjunctivitis

Indexed keywords

EID: 77953429940     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.3.397     Document Type: Article

References (86)

1. Key B. Allergy and allergic diseases. Part I. N. Engl. J. Med. 344, 30–37 (2001).
2. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. 115, 118–122 (2005).
3. Leonardi A. Emerging drugs for ocular allergy. Expert Opin. Emerg. Drugs 10, 505–520 (2005).
4. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog. Ret. Eye Res. 21, 319–339 (2002).
5. Blepharitis and Conjunctivitis. Guidelines for Diagnosis and treatment. BenEzra D (Ed.). Editorial Glosa, Barcelona, Spain (2006).
6. Wilson FM. Allergy to topical medication. Int. Ophthalm. Clin. 43, 73–81 (2003).
7. Motterle L, Diebold Y, Enriquez de Salamanca A et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch. Ophthalmol. 124 (4), 462–468 (2006).
8. Kumagai N, Fukuda K, Fujitsu Y, Yamamoto K, Nishida T. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog. Retin. Eye Res. 25 (2), 165–187 (2006).
9. Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-γ, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin. Exp. Allergy 30 (1), 103–109 (2000).
10. Calder VL, Jolly G, Hingorani M et al. Cytokine production and mRNA expression by conjunctival T cell lines in chronic allergic eye diseases. Clin. Exp. Allergy 29 (9), 1214–1222 (1999).
11. Miyazaki D, Nakamura T, Toda M, Cheung-Chau KW, Richardson RM, Ono SJ. Macrophage inflammatory protein-1α as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J. Clin. Invest. 115 (2), 434–442 (2005).
12. Anderson DF, Zhang S, Bradding P et al. The relative contribution of mast cell subsets to conjunctival T(H)2-like cytokines. Invest. Ophthalmol. Vis. Sci. 42 (5), 995–1001 (2001).
13. Cook EB, Stahl JL, Barney NP, Graziano FM. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr. Drug Targets Inflamm. Allergy 1 (2), 167–180 (2002).
14. Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol. Scand. 230 (Suppl.), 18–21 (2000).
15. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr. Opin. Allergy Clin. Immunol. 5 (5), 437–440 (2005).
16. Tanaka S, Ichikawa A. Recent advances in molecular pharmacology of the histamine systems: immune regulatory roles of histamine produced by leukocytes. J. Pharmacol. Sci. 101, 19–23 (2006).
17. Mans BJ. Tick histamine-binding proteins and related lipocalins: potential as therapeutic agents. Curr. Opin. Investig. Drugs 6 (11), 1131–1135 (2005).
18. Abu El-Asrar AM, Struyf S, Van Damme J, Geboes K. Role of chemokines in vernal keratoconjunctivitis. Int. Ophthalmol. Clin. 43, 33–39 (2003).
19. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin. Exp. Allergy 36, 777–784 (2006).
20. Leonardi A, Jose P, Zhan, Calder V. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 110, 487–492 (2003).
21. Nakamura T, Ohbayashi M, Toda M, Hall DA, Horgan CM, Ono SJ. A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol. Res. 33 (3), 213–221 (2005).
22. Metz DP, Bacon AS, Holgate S, Lightman SL. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J. Allergy Clin. Immunol. 98, 686–696 (1996).
23. Montan PG, Scheynius A, van der Ploeg I. Similar T helper Th2-like cytokine mRNA expression in vernal keratoconjunctivitis regardless of atopic constitution. Allergy 57, 436–441 (2002).
24. Leonardi A, Fregona IA, Plebani M, Secchi AG, Calder VL. Th1- and Th2-type cytokines in chronic ocular allergy. Graefes Arch. Clin. Exp. Ophthalmol. 244 (10), 1240–1245 (2006).
25. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy. T-cell tolerance and more. Allergy 61 (7), 796–807 (2006).
26. Leonardi A, Brun P, Abatangelo G, Plebani M, Secchi AG. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 44, 3052–3058 (2003).
27. Leonardi A, Brun P, Sartori MT et al. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 46, 1364–1370 (2005).
28. Ghavami S, Hashemi M, de Serres FJ, Naghibzadeh Bajestani S, Mehrabifar H, Leonardi A. Trypsin inhibitory capacity in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 48 (1), 264–269 (2007).
29. Miyazaki D, Liu G, Clark L, Ono SJ. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest. Ophthalmol. Vis. Sci. 41 (12), 3850–3855 (2000).
30. Fukushima A, Ozaki A, Jian Z et al. Dissection of antigen-specific humoral and cellular immune responses for the development of experimental immune-mediated blepharoconjunctivitis in C57BL/6 mice. Curr. Eye Res. 30 (4), 241–248 (2005).
31. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Yagita H, Ueno H. Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40. Invest. Ophthalmol. Vis. Sci. 47 (2), 657–663 (2006).
32. Fukushima A, Yamaguchi T, Ishida W et al. Engagement of 4–1BB inhibits the development of experimental allergic conjunctivitis in mice. J. Immunol. 175 (8), 4897–4903 (2005).
33. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65, 215–228 (2005).
34. Secchi A, Ciprandi G, Leonardi A et al. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Acta Ophthalmol. Scand. 78 (230), 42–47 (2000).
35. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol. 79, 541–545 (1997).
36. Leonardi A, Borghesan F, Avarello A, Plebani M, Secchi AG. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br. J. Ophthalmol. 81, 23–26 (1997).
37. Santos CI, Huang AJ, Abelson MB et al. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am. J. Ophthamol. 117, 488–497 (1994).
38. Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL. Pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, Phase III studies. J. Ocul. Pharmacol. Ther. 18, 475–488 (2002).
39. Bouhlal H, Blondin C, Haeffner-Cavaillon N, Goldschmidt P. N acetyl-aspartyl glutamic acid (NAAGA) inhibits the adhesion of leukocytes to activated endothelial cells and down-modulates the cytokine-induced expression of adhesion molecules. J. Fr. Ophtalmol. 25, 993–1000 (2002).
40. Dell SJ, Lowry GM, Northcutt JA et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J. Allergy Clin. Immunol. 102, 251–255 (1998).
41. Leonardi A, Papa V, Milazzo G, Secchi AG. Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. Cornea 21, 476–481 (2002).
42. Ciprandi G, Buscaglia S, Catrullo A et al. Azelastine eye drops reduce and preventallergic conjunctival reaction and exert anti-allergic activity. Clin. Exp. Allergy 27, 182–191 (1997).
43. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 16 (5), 318–322 (1985).
44. Lytinas M, Kempuraj D, Huang M et al. Azelastine’s inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc. 23 (1), 45–51 (2002).
45. Kempuraj D, Huang M, Kandere K et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann. Allergy Asthma Immunol. 88 (5), 501–506 (2002).
46. Friedlander MH, Harris J, LaVallee N et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 107, 2152–2157 (2000).
47. Kamei C, Akagi M, Mio M et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol. Immunotoxicol. 14 (1–2), 191–205 (1992).
48. Amon U, Gibbs BF, Buss G, Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm. Res. 49 (3), 112–116 (2000).
49. Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin. Ther. 26 (1), 35–47 (2004).
50. Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin. Ther. 26 (1), 29–34 (2004).
51. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J. Ocul. Pharmacol. Ther. 19 (1), 75–81 (2003).
52. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther. 27 (9), 1392–1402 (2005).
53. Kidd M, McKenzie SH, Steven I, Cooper C, Lanz R; Australian Ketotifen Study Group. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br. J. Ophthalmol. 87 (10), 1206–1211 (2003).
54. Greiner JV, Mundorf T, Dubiner H et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am. J. Ophthalmol. 136 (6), 1097–1105 (2003).
55. Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr. Allergy Immunol. 15, 551–557 (2004).
56. Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin. Ther. 25 (7), 1975–1987 (2003).
57. Hasala H, Malm-Erjefalt M, Erjefalt J et al. Ketotifen induces primary necrosis of human eosinophils. J. Ocul. Pharmacol. Ther. 21 (4), 318–327 (2005).
58. Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm. 11 (4), 247–268 (2003).
59. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother. 5, 1979–1994 (2004).
60. Rosenwasser LJ, O’Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of preclinical and clinical research. Curr. Med. Res. Opin. 21 (9), 1377–1387 (2005).
61. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. 25, 2539–2552 (2003).
62. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol. 87 (5), 424–429 (2001).
63. Cook EB, Stahl JL, Brooks AM, Graziano FM, Barney NP. Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest. Ophthalmol. Vis Sci. 47 (8), 3423–3429 (2006).
64. Cook EB, Stahl JL, Sedgwick JB, Barney NP, Graziano FM. The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells. Ann. Allergy Asthma Immunol. 92 (1), 65–67 (2004).
65. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 22 (7), 826–833 (2000).
66. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr. Med. Res. Opin. 20, 1167–1173 (2004).
67. Finegold I, Granet DB, D’Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin. Ther. 28 (10), 1630–1638 (2006).
68. Berger W, Abelson MB, Gomes PJ et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann. Allergy Asthma Immunol. 95 (4), 361–371 (2005).
69. Alexander M, Berger W, Buchholz P et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual. Life Outcomes 3, 67 (2005).
70. Smith AF, Pitt AD, Rodruiguez AE et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol. 12 (4), 233–242 (2005).
71. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117 (2), 319–325 (2006).
72. Ikeda H, Tsukamoto H, Sato E, Mishima HK, Kihira K. Daily cost of ophthalmic solutions used to treat allergic conjunctivitis in Japan. Ophthalmic Epidemiol. 11, 35–42 (2004).
73. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. 11, 17–33 (2004).
74. Guest JF, Clegg JP, Smith AF. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK. Curr. Med. Res. Opin. 22, 1777–1785 (2006).
75. Williams PB, Sheppard JD Jr. Omalizumab: a future innovation for treatment of severe ocular allergy? Expert Opin. Biol. Ther. 5, 1603–1609 (2005).
76. Abelson MB, Gomes PJ, Vogelson CT et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr. Med. Res. Opin. 21 (5), 683–691 (2005).
77. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J. Allergy Clin. Immunol. 117, 1214–1225 (2006).
78. BenEzra D, Pe’er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am. J. Ophthalmol. 101, 278–282 (1986).
79. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am. J. Ophthalmol. 110, 137–142 (1990).
80. Pucci N, Novembre E, Cianferoni A et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann. Allergy Asthma Immunol. 89, 298–303 (2002).
81. Hingorani M, Calder VL, Buckley RJ, Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 40, 392–399 (1999).
82. Akpek EK, Dart JK, Watson S et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 111, 476–482 (2004).
83. Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br. J. Ophthalmol. 90 (4), 461–464 (2006).
84. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am. J. Ophthalmol. 135, 297–302 (2003).
85. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J. Allergy Clin. Immunol. 113, 355–358 (2004).
86. Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol. Scand. 84 (5), 693–695 (2006).